| GENMAB AS DK 1 | 307.600 / +1.52% |
| Date/Time | 05/07 / 16:59 |
| Chg. / Chg.(%) | 4.600 / +1.52% |
| Bid | - |
| Ask | - |
| Open | 309.500 |
| Previous Close | 303.000 |
| High | 309.500 |
| Low | 303.000 |
| Volume [EUR] | 0.000 |
| Volume [Units] | 0 |
| Price fixings | 4 |
| ISIN | DK0010272202 |
| Security | GE9 |
| Exchange | Stuttgart |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 303.50 |  |
|
| OMX Nordic | 2,295.00 |  |
151,551 |
| Cboe Europe .. | 2,295.00 | |
33,303 |
| London Inter.. | 2,290.5 | |
28,760 |
| Turquoise | 2,295.00 | |
16,400 |
| Nasdaq Other.. | 381.1700 | |
95 |
| TradeGate | 307.800 | |
72 |
| Frankfurt | 306.3000 | |
30 |
| Cboe Europe .. | 2,281.50 | |
19 |
| Cboe Europe .. | 2,295.00 | |
5 |
| Vienna Globa.. | 308.90 | |
0 |
| München | 307.40 | |
0 |
| Düsseldorf | 307.30 | |
0 |
| Berlin | 308.80 | |
0 |
| Stuttgart | 307.600 | |
0 |
| gettex | 307.400 | |
|
| Mexico | 7,638.15 |  |
11,330 |
News
- Genmab Announces Financial Results for the First Quarter of 2021
05/05/2021 / 17:01 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
04/20/2021 / 12:34 - GlobeNewswire - Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/25/2021 / 20:53 - GlobeNewswire
Real-time